What Does Remission Look Like After Gigantism Treatment? Hormone Levels and MRI Follow-Up

The follow-up letter arrives a few months after the operation, and it is mostly numbers. An IGF-1 value with a reference range beside it. A growth hormone result written to one decimal place. A line about the MRI that says something like ‘post-surgical change, no definite residual’. For a young person who spent years being the tallest in every photograph, and for the parents who watched shoe sizes climb, that letter is supposed to be the finish line. It rarely feels like one.

That gap between the lab report and lived experience is where most confusion about gigantism treatment results begins. People expect remission to look like something. Shoulders that stop broadening, hands that shrink back, a face that resets. Some of that happens, slowly. Much of it does not, and its absence says nothing about whether the treatment worked.

This explainer walks through what endocrinologists actually measure, why they measure it on the schedule they do, and how to read the results with realistic hope.

What remission actually means in gigantism treatment results

Gigantism is excess growth hormone produced before the growth plates in the long bones have closed, almost always because of a benign pituitary tumor called an adenoma. The pituitary is the pea-sized gland at the base of the brain that directs most other hormone glands. When the same excess begins after the growth plates have fused, the condition is called acromegaly, and because most people with gigantism eventually reach adulthood, the two conditions share their follow-up rules (MedlinePlus).

Remission, in this setting, is a biochemical word. The Endocrine Society’s clinical guideline on acromegaly defines it by two hormone measurements: an IGF-1 level that is normal for the person’s age, and a growth hormone level that either sits below a low threshold on a random sample or drops below an even lower threshold during a glucose suppression test. IGF-1, or insulin-like growth factor 1, is the hormone the liver releases in response to growth hormone; it is the steadier, more readable signal of the two.

Notice what is missing from that definition. Height is not in it. Ring size is not in it. Whether the MRI shows a small scar or a small fragment of leftover tissue is not, strictly, in it either. A person can be in biochemical remission with visible tumor remnant, and a person can have a clean-looking scan while hormones remain high.

Endocrinologists also use a second category, ‘controlled’, for someone whose hormones are normal only while taking medicine. It is a genuinely good outcome, but it is not the same as remission, and the distinction matters when the question of stopping or tapering treatment arises later. That decision always belongs to the treating team, not to a single lab value.

How gigantism treatment works: what happens to the tumor and the hormones

Every treatment for gigantism aims at the same target from a different angle: reduce the amount of growth hormone reaching the bloodstream, and keep the tumor from pressing on neighboring structures such as the optic nerves.

Surgery is usually the first approach when the tumor looks removable. In a transsphenoidal operation, the surgeon reaches the pituitary through the nose and the sphenoid sinus, a hollow space behind it, using an endoscope or microscope, so there is no incision on the face or scalp (Mayo Clinic). If the whole adenoma comes out, growth hormone can fall within hours, because the tumor cells that were pumping it out are gone. IGF-1 lags behind; the liver takes weeks to reset.

Medicines work while the tumor stays in place. Somatostatin analogs mimic a natural brake hormone and tell tumor cells to release less growth hormone; some tumors also shrink. Dopamine agonists act on a different receptor and help a smaller share of tumors. A growth hormone receptor antagonist does something different again: it does not touch the tumor at all but blocks growth hormone from docking onto cells, so IGF-1 falls even though measured growth hormone may rise (Mayo Clinic). Which class, if any, is appropriate is a decision for the prescribing endocrinologist.

Radiation therapy damages the DNA of tumor cells so they gradually stop dividing and secreting. Its effect builds over years rather than weeks, which shapes how follow-up after radiation is scheduled (NHS).

In practice, gigantism often needs more than one of these. In an international series of 208 people with pituitary gigantism, most tumors were large at diagnosis and multimodal treatment was common, reflecting how aggressive these adenomas can be in the young (PubMed, Rostomyan et al.).

Who is usually offered each treatment, and who is usually asked to wait

The sequence of treatment is rarely identical for two people, but the reasoning follows recognizable lines.

Surgery tends to be offered first when imaging suggests the tumor can be removed safely, when vision is threatened, or when the person is young enough that ongoing growth hormone excess would keep adding height and joint strain. Growth plates are the reason urgency differs from adult acromegaly: while they remain open, every month of uncontrolled hormone adds irreversible bone length (Cleveland Clinic).

Medicines are typically considered when surgery is not possible, when a tumor has grown into the cavernous sinuses (the venous channels on either side of the pituitary, which surgeons cannot fully clear), or when hormones stay high after an operation. Some teams also use medicine for a period before surgery in selected cases, though the evidence for a benefit on final outcome is mixed, and the Endocrine Society guideline treats it as an option rather than a rule.

Radiation is usually reserved for tumor that persists after surgery and does not respond adequately to medicine, because its benefit is slow and because it carries a meaningful long-term risk of the pituitary losing other functions (NHS).

Who waits? Someone with a small remnant that is not growing and hormones that are normal or nearly normal may be watched with periodic scans and blood tests rather than sent straight to a second operation or radiation. Waiting here is not neglect; it is a strategy built on the knowledge that residual tissue often stays quiet for years. The team weighs tumor location, hormone trend, age, and other pituitary functions, and the balance can shift as new results come in.

Why IGF-1 levels after pituitary surgery are the number your team watches most

Growth hormone is released in pulses, mostly at night, with bursts and troughs that can vary tenfold across a single day. A random growth hormone sample is therefore a snapshot of a moving target. IGF-1 behaves differently. It is produced steadily by the liver in response to the average growth hormone exposure over roughly the preceding day, and it changes slowly. That stability is exactly why it anchors the definition of remission (Endocrine Society guideline, PubMed).

Two features of IGF-1 trip people up when they read their own results.

First, the normal range depends heavily on age. IGF-1 peaks naturally during puberty and then declines across adult life. A value that would be alarming in a forty-year-old may be entirely expected in a fifteen-year-old, which is why laboratories report it against age-matched reference ranges and why comparing your number to someone else’s is rarely useful.

Second, IGF-1 is slow to fall after successful surgery. Growth hormone may normalize within a day; IGF-1 can take several weeks to reach its new baseline. Checking it too early gives a falsely high reading and unnecessary worry. The Endocrine Society guideline recommends measuring IGF-1 and growth hormone at about 12 weeks after surgery for this reason, and then following IGF-1 at least yearly once stable.

Other factors can nudge IGF-1 without any change in the tumor. Poorly controlled diabetes, liver disease, severe undernutrition, and untreated low thyroid or sex hormone levels can all lower or distort it. An endocrinologist reading a borderline value will consider these before concluding anything about disease activity. A single result is a data point; the direction of travel across visits is the story.

What does the growth hormone suppression test show after treatment?

In a healthy person, a sudden rise in blood sugar switches growth hormone production almost off. Tumor cells ignore that signal. The growth hormone suppression test, also called an oral glucose tolerance test for growth hormone, exploits this difference. After an overnight fast, you drink a standard sugary solution, and blood is drawn several times over about two hours. If growth hormone falls below a very low threshold at its lowest point, the pituitary is behaving normally (Mayo Clinic).

The Endocrine Society guideline sets that lowest-point threshold below 1 microgram per liter for the classic definition of remission, and notes that highly sensitive modern assays may justify a stricter cut-off below 0.4 micrograms per liter. These are laboratory values, not treatment targets you should try to reach on your own; they simply describe what ‘suppressed’ means on paper.

The test is most useful after surgery or radiation, when the question is whether the remaining pituitary tissue has regained normal control. It is not interpretable while someone is taking a growth hormone receptor antagonist, because that medicine raises measured growth hormone by design, and it can be misleading during somatostatin analog treatment. Your team will tell you which tests apply to your situation.

A few situations can produce a false ‘failure’ to suppress. Adolescence itself can blunt suppression, as can diabetes, liver disease, kidney disease and some other medicines. Conversely, some people with active disease show adequate suppression yet have an elevated IGF-1. Endocrinologists call this a discordant result, and it is common enough that guidelines instruct them to weigh IGF-1 more heavily and to repeat testing rather than declare victory or defeat on one afternoon’s numbers.

What the first 12 weeks after pituitary surgery usually look like

The days immediately after a transsphenoidal operation are about the body, not the tumor. Nasal stuffiness, headache and fatigue are expected. Teams watch closely for two specific problems: leakage of cerebrospinal fluid through the nose, and disturbances in salt and water balance caused by the pituitary’s neighboring hormone systems being bruised. Sodium levels are checked repeatedly in the first one to two weeks, and people are often asked to report unusual thirst, very frequent urination, or confusion (Mayo Clinic).

Hormone recovery unfolds in layers. Growth hormone may already be low in the first days. Cortisol, the stress hormone directed by the pituitary, is often measured within the first week to see whether the gland can still produce it, and some people go home on temporary steroid cover until that is clear; whether and how that is done is a decision for the surgical and endocrine teams. Thyroid and sex hormones are usually reassessed over the following weeks to months.

Around 12 weeks, the first definitive check arrives: IGF-1, a growth hormone measurement or suppression test, and an MRI (Endocrine Society guideline). Scanning earlier than this is usually avoided because post-operative swelling, blood and packing material can look like tumor and lead to needless anxiety or premature intervention.

People often notice softening of facial features, less hand swelling and easier breathing at night within weeks, sometimes before the blood tests confirm anything. These early changes reflect fluid shifts as growth hormone falls; they are encouraging but not proof. Others feel little different, and that is not proof of failure. The 12-week results, read together, are the first honest answer.

Pituitary MRI follow-up: what the scan can and cannot tell you

MRI answers a structural question: is there tumor tissue, and is it changing? It cannot say whether that tissue is making hormone. The two kinds of information have to be read side by side.

The first post-operative scan, typically around 12 weeks, becomes the new baseline against which all later scans are compared (Endocrine Society guideline). Radiologists describe what they see in cautious language, and a few terms come up repeatedly. ‘Post-surgical change’ means scar, fat graft or packing. ‘Residual’ means tissue that looks like adenoma left behind, often deliberately, because it was wrapped around a nerve or artery. ‘Indeterminate’ means the picture is genuinely unclear, and the honest answer is to look again later.

How often scans are repeated depends on that baseline. Someone in biochemical remission with no visible residual may need only occasional imaging, driven mainly by any later rise in IGF-1 or new symptoms. Someone with a known remnant is usually scanned at intervals, initially yearly, to confirm it is stable, with the interval lengthening if nothing changes. After radiation, imaging continues for many years because tumor shrinkage and any late effects on the surrounding pituitary evolve slowly (NHS).

A pituitary MRI uses a dedicated protocol with thin slices and a contrast agent, so it is more detailed than a general brain MRI; if you have scans done in different places, the team may want them on the same protocol for fair comparison. Bring prior images if asked.

One reassuring truth: a stable remnant on serial scans, with normal hormones, is a recognized good outcome, not an unfinished job.

Acromegaly remission criteria at a glance: remission, controlled, discordant, persistent

Because gigantism follows the same hormone rules as acromegaly once growth ends, the categories used in adult follow-up apply. The table summarizes how endocrinologists usually classify results, drawing on the Endocrine Society guideline and Mayo Clinic descriptions. Thresholds are laboratory definitions, not personal targets, and individual laboratories vary.

Category	IGF-1 (age-matched)	Growth hormone	MRI	What it usually means
Surgical remission	Normal	Suppresses to a very low level on glucose testing, or low on random sample	No residual, or stable post-surgical change	Tumor removed; long-term monitoring for recurrence
Controlled on medicine	Normal	Normal or low on random sample (suppression test not reliable on some medicines)	Stable or shrinking residual	Disease active but managed; medicine continues under review
Discordant	Elevated with suppressed growth hormone, or the reverse	Does not match IGF-1	Variable	Repeat testing; IGF-1 weighted more heavily; look for other causes
Persistent disease	Elevated	Fails to suppress	Residual often visible, may be growing	Further treatment discussed: repeat surgery, medicine, radiation
Recurrence	Was normal, now rising	Rising or failing to suppress	New or enlarging tissue	Reassessment as for persistent disease

Two points about this table deserve emphasis. Classification can change over time in either direction, which is why follow-up is lifelong. And ‘controlled’ is not a consolation prize: normal IGF-1, by whatever route, is associated in observational studies with the improvements in health that matter, including blood pressure, sleep and metabolic risk (Mayo Clinic). The route affects convenience and side-effect burden; the destination is the same.

Can acromegaly be reversed? What changes, what stays

This is the question behind almost every conversation about gigantism treatment results, and the honest answer has two halves.

What reverses: the soft-tissue effects of growth hormone excess. Facial puffiness, thickened skin, swollen hands and feet, and the excess sweating that many people find most bothersome generally improve over months once IGF-1 normalizes, because they are driven by fluid retention and tissue swelling rather than fixed structural change (NHS). Sleep apnea often lessens as airway soft tissue shrinks, though it should be reassessed rather than assumed gone. Blood sugar and blood pressure frequently improve. Headache related to tumor pressure may resolve quickly after surgery.

What does not reverse: bone. Height already reached is permanent, because growth hormone lengthened bone through growth plates that cannot be un-lengthened. A widened jaw, prominent brow, enlarged hands and feet, and spaced teeth reflect bone remodeling and remain, although the soft tissue over them may thin enough that features look less heavy. Joint cartilage damaged by years of excess growth can leave lasting arthritis, which is why joint care continues after hormones normalize (Cleveland Clinic).

Between those halves sits the heart. Growth hormone excess thickens the heart muscle; with early and sustained control this can partially regress, but longstanding changes may not fully resolve, so cardiac follow-up is often kept up even in remission (Mayo Clinic).

Reversal, then, is real but selective. The purpose of treatment is to stop the process, protect the organs that are still protectable, and remove the tumor’s threat to vision and the rest of the pituitary. Measured against that purpose, normal IGF-1 is the outcome that counts, whatever the mirror shows.

Medicines and radiation when surgery leaves disease behind: mechanisms and typical timelines

Roughly speaking, the larger and more invasive the adenoma at diagnosis, the less likely surgery alone will achieve remission, and gigantism tumors are often large (PubMed, Rostomyan et al.). Many people therefore move to a second phase of treatment. What follows describes how these options work and how long they typically take to show their effect, not what anyone should take; those decisions rest with the endocrinologist.

Somatostatin analogs, given by injection at intervals set by the prescriber, bind receptors on tumor cells and dampen growth hormone release. IGF-1 usually begins to fall over the first weeks, with the full picture emerging over about three months, which is why response is often judged at that point (Mayo Clinic). Gallbladder sludge or stones and digestive upset are recognized side effects, and blood sugar can move in either direction.

Dopamine agonists are taken by mouth and help a minority of growth hormone tumors, more often those that also make prolactin. Their effect on IGF-1 is usually modest.

The growth hormone receptor antagonist blocks the hormone’s action in tissues rather than its release. IGF-1 falls, often within weeks, while measured growth hormone rises; liver tests are monitored, and because the tumor itself is untouched, MRI surveillance continues (Mayo Clinic).

Radiation, whether delivered in a single focused session or over several weeks, acts slowly. The NHS notes it can take years to reach its full effect, and medicine is often continued in the meantime. The main long-term risk is loss of other pituitary hormone functions, which develops gradually in a substantial proportion of people over the following decade, so hormone panels are checked yearly after radiation even when IGF-1 looks fine.

What are the symptoms of a damaged pituitary gland after treatment?

Treating a growth hormone tumor can leave the rest of the pituitary bruised, scarred or, after radiation, slowly failing. Doctors call this hypopituitarism: a shortfall in one or more of the hormones the gland normally directs. It is a known trade-off of every treatment on this page, and it is the reason follow-up blood work covers far more than IGF-1 (NHS).

The pattern of deficiency tends to be gradual and non-specific, which is exactly why teams test for it rather than waiting for people to notice. Cortisol shortfall shows up as deep fatigue, low blood pressure, nausea and poor tolerance of illness, and it is the deficiency that can become dangerous fastest. Thyroid hormone shortfall brings sluggishness, cold intolerance and weight change over months. Low sex hormones affect periods, libido, energy and, over years, bone density. Growth hormone deficiency, ironically, can follow treatment of growth hormone excess, particularly after radiation, and contributes to tiredness and altered body composition. Damage to the pituitary’s back portion can cause the intense thirst and heavy urination of diabetes insipidus, which despite its name has nothing to do with blood sugar (MedlinePlus).

None of these should be self-diagnosed from a description. Fatigue after a major operation, or during adolescence, has many ordinary explanations. What matters is that the endocrine team checks cortisol, thyroid, sex hormone and, where relevant, water-balance markers at planned intervals, more frequently in the first year and yearly thereafter, and that you report new or worsening symptoms between visits rather than attributing them to stress.

If deficiencies are found, replacement therapy is available for each hormone; whether, when and how it is used is a decision the treating team makes with you.

Can you live a normal life with a pituitary adenoma? Long-term gigantism treatment results

Most people who reach and hold normal IGF-1 go on to work, study, have relationships and families, and pursue sport within the limits their joints allow. Observational evidence in acromegaly suggests that sustained biochemical control brings health risks much closer to those of the general population, whereas uncontrolled growth hormone excess is associated with higher rates of cardiovascular disease, diabetes and sleep apnea (Mayo Clinic; Endocrine Society guideline). That is the practical meaning of the numbers on the follow-up letter.

Living well with a treated adenoma does involve a permanent relationship with an endocrinology service. A typical rhythm after remission is an IGF-1 check at least yearly, other pituitary hormones yearly, MRI when hormones or symptoms change or on a set schedule if a remnant exists, and periodic attention to the organs growth hormone affected: blood pressure, blood sugar, sleep, joints and, in adults who had years of exposure, colon screening according to the team’s advice (Endocrine Society guideline).

Gigantism adds two considerations. First, a substantial share of cases have an identifiable genetic cause, most often changes in the AIP gene or duplications on the X chromosome, so genetic counseling is frequently offered and may have implications for relatives (PubMed, Rostomyan et al.). Second, the transition from pediatric to adult care is a vulnerable moment; follow-up sometimes lapses just as a young person becomes responsible for it. Asking early how that handover will work is worth the awkwardness.

Recurrence after apparent remission is uncommon but real, can occur many years later, and is usually caught first by a rising IGF-1 rather than by symptoms. That single fact justifies the lifelong blood tests.

What people often get wrong about gigantism treatment results

Myth: the pituitary can be activated or calmed naturally with diet, supplements or exercise. Searches for how to ‘activate the pituitary gland naturally’ are common, and for a hormone-secreting adenoma the answer is that no food, herb or routine has been shown to shrink the tumor or normalize IGF-1. Sleep, nutrition and exercise support general health and recovery; they do not substitute for monitoring or treatment, and some supplements can interfere with hormone assays. Tell your team about anything you take.

Myth: a clean MRI means the disease is gone. Hormone activity, not scan appearance, defines remission. Microscopic tumor invisible on imaging can keep IGF-1 elevated.

Myth: a visible remnant means the operation failed. Surgeons often leave tissue deliberately to protect nerves and arteries. A stable remnant with normal hormones is a recognized good result.

Myth: normal growth hormone on one blood test settles the matter. Growth hormone pulses; a single random value can be normal in active disease and mildly high in remission. IGF-1 and, where appropriate, a suppression test carry more weight (Endocrine Society guideline).

Myth: once in remission, follow-up can stop. Recurrence can appear years later and is usually silent at first.

Myth: height and features will return to what they would have been. Bone changes are permanent; soft-tissue changes improve.

Myth: feeling well means hormones are normal, and feeling tired means they are not. Fatigue after treatment has many causes, including other pituitary hormone shortfalls that need their own tests. The blood work, not the feeling, is the guide.

Questions to ask your care team about hormone levels and MRI follow-up

Consultations are short and results letters are terse. A written list, taken to each appointment, turns a passive review into a real conversation. These are questions endocrinologists generally welcome.

• Which category do my current results place me in: remission, controlled, discordant or persistent, and what would change that?
• What is my IGF-1 compared with the age-matched range, and what direction has it moved since the last check?
• Do I need a growth hormone suppression test, or does the medicine I take make it uninterpretable?
• Is there residual tumor on my MRI? If so, is it stable, and how often will it be rescanned?
• Which other pituitary hormones are being checked, how often, and what would prompt replacement?
• If I am on medicine, what is the plan for reviewing whether it is still needed, and what side effects should I report?
• If radiation is part of my treatment, over what timeframe do you expect its effect, and how will late effects be monitored?
• Should I or my family be offered genetic testing, and what would a result change?
• Which of my joint, heart, sleep or metabolic issues should still be followed even if hormones are normal?
• How will my care transfer from pediatric to adult services, and who coordinates it?
• What symptoms should make me contact you between scheduled visits?

Ask, too, for copies of your results and imaging reports. Carrying your own record protects you when you move, change insurers or see a clinician who does not know your history, and it lets you watch the trend that matters most: the direction of IGF-1 over years.

When to call your doctor

Most of the follow-up described here happens on a calendar. Some things should not wait for it.

Seek urgent medical care, by emergency services if needed, for a sudden severe headache unlike any before, especially with vomiting, double vision, drooping eyelid or sudden loss of vision. This can signal bleeding into a pituitary tumor, known as pituitary apoplexy, which is rare but time-critical (Mayo Clinic). The same urgency applies to clear fluid dripping steadily from the nose after surgery, fever with stiff neck, or, in someone with known or suspected cortisol deficiency, vomiting, dizziness, confusion or collapse during an illness, which can indicate adrenal crisis.

Contact your endocrine team promptly, within days, if you notice intense thirst with very frequent urination, a return of hand or facial swelling and sweating, new or worsening snoring with daytime sleepiness, worsening joint pain, persistent deep fatigue, unexpected changes in periods or libido, or headaches that are becoming more frequent. None of these confirms recurrence or hormone deficiency, but each is a reason to move a blood test forward rather than wait for the annual check.

Call as well if you have missed follow-up for more than a year, are moving between pediatric and adult services, or have started any new medicine or supplement that the team does not know about, since several can alter hormone results.

Your team would rather hear from you about a symptom that turns out to be nothing than miss a change that a simple IGF-1 test could have caught. Every treatment decision that follows from a call sits with them, but the call itself is yours to make.

Frequently asked questions

What are the acromegaly remission criteria that also apply to gigantism?

Remission means an IGF-1 level normal for age together with growth hormone that falls to a very low level on a glucose suppression test or is low on a random sample, according to the Endocrine Society guideline. Because people with gigantism follow the same hormone rules once growth ends, the same criteria are used. MRI findings are read alongside, but hormones define remission.

How soon after pituitary surgery are IGF-1 levels checked?

Usually around 12 weeks after the operation. Growth hormone can normalize within a day of successful surgery, but IGF-1 is produced by the liver and takes several weeks to reach its new baseline, so an earlier test can look falsely high. After that first check, IGF-1 is typically measured at least yearly, more often if results are borderline.

What is the growth hormone suppression test and why do I need it after treatment?

It checks whether your pituitary has regained normal control. After an overnight fast you drink a standard sugary solution and blood is drawn over about two hours. In healthy tissue, the sugar load switches growth hormone almost off; tumor cells ignore it. The test is not reliable while taking certain medicines, so your team will tell you whether it applies.

How often is pituitary MRI follow up repeated after gigantism treatment?

It depends on the baseline scan taken about 12 weeks after surgery. With no visible residual and normal hormones, further scans are often driven by any change in IGF-1 or symptoms. With a known remnant, imaging is usually repeated yearly at first, then less often if stable. After radiation, scans continue for many years because changes evolve slowly.

Can acromegaly be reversed once hormones are controlled?

Partly. Soft-tissue effects such as swelling of the hands and face, thickened skin, sweating and often sleep apnea improve over months once IGF-1 normalizes. Bone changes, including height, jaw width and enlarged hands and feet, are permanent, and joint damage may persist. Heart muscle thickening can partially regress with sustained control, which is why cardiac follow-up often continues.

Can you live a normal life with a pituitary adenoma that has been treated?

Most people who achieve and maintain normal IGF-1 live full lives, and observational evidence suggests their health risks move much closer to those of the general population. What remains is lifelong follow-up: yearly hormone checks, MRI when indicated, and attention to joints, sleep, blood pressure and blood sugar. Recurrence is uncommon but can be silent, which is why testing continues.

How to activate the pituitary gland naturally after gigantism treatment?

There is no diet, supplement or exercise shown to shrink a growth hormone tumor, normalize IGF-1 or restore pituitary function. Good sleep, nutrition and activity support recovery and general health but do not replace monitoring or prescribed treatment. Some supplements can interfere with hormone assays, so tell your endocrine team about everything you take.

What are the symptoms of a damaged pituitary gland after surgery or radiation?

Shortfalls in other pituitary hormones tend to develop gradually and feel non-specific: deep fatigue, low blood pressure or nausea with cortisol deficiency, sluggishness and cold intolerance with low thyroid, changes in periods or libido with low sex hormones, and intense thirst with heavy urination if water balance is affected. These are diagnosed by planned blood tests, not by self-assessment, so report new symptoms to your team.

What does a discordant result mean in my gigantism treatment results?

It means IGF-1 and growth hormone disagree, for example a normal suppression test with elevated IGF-1 or the reverse. This is common enough that guidelines address it directly. Endocrinologists usually weight IGF-1 more heavily, look for other causes such as adolescence, diabetes, liver or kidney problems, and repeat testing before changing anything.

Why does follow-up continue for years if I am in remission?

Because recurrence can occur many years after apparent remission and is usually detected first by a rising IGF-1 rather than by symptoms. Follow-up also watches for late loss of other pituitary hormones, particularly after radiation, and for the heart, joint, sleep and metabolic effects of past growth hormone excess, which need their own care even when hormones are normal.

References

• MedlinePlus Medical Encyclopedia: Gigantism
• NHS: Acromegaly
• Cleveland Clinic: Gigantism

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.